Novo Nordisk aims for FDA approval of weight loss pill

NBC News•Wednesday, September 17, 2025 at 11:03:36 PM

Novo Nordisk is making strides towards FDA approval for its new weight loss pill, which shows promise in achieving similar results to its injectable counterpart, Ozempic. This development is significant as it could provide a more convenient daily option for those seeking to manage their weight effectively. With the Chief Scientific Officer expressing optimism about the approval this year, it highlights the company's commitment to advancing treatment options in the weight loss sector.

— Curated by the World Pulse Now AI Editorial System

Read Original

Was this article worth reading? Share it

Recommended Readings

Dow Jones - Health13 hours ago

Eli Lilly’s Diabetes Drug Tops Novo Nordisk’s Oral Pill in Trial

PositiveHealth

Eli Lilly's new diabetes drug has outperformed Novo Nordisk's oral semaglutide in clinical trials, showing significant improvements in blood sugar levels and weight loss for patients with Type 2 diabetes. This is a big deal because it could offer better treatment options for millions struggling with diabetes, potentially leading to improved health outcomes and quality of life.

Read full article

via Dow Jones - Health

ABC Newsa day ago

FDA takes aim at Hims and other telehealth services in drug advertising blitz

NegativeHealth

The FDA has launched a crackdown on telehealth services like Hims, warning them about advertising unofficial versions of popular medications, including Wegovy, a leading obesity treatment. This move is significant as it highlights the growing concern over the safety and regulation of online health services, which have surged in popularity. The implications of these warnings could reshape how telehealth companies operate and ensure that patients receive safe and approved treatments.

Read full article

via ABC News

Dow Jones - Health2 days ago

Novo Nordisk’s Wegovy Helps Suppress Thoughts About Food, Study Suggests

PositiveHealth

A new study shows that Novo Nordisk's Wegovy significantly reduces constant thoughts about food, with a reported decline of 46% among users after starting treatment.

Editor’s Note: This finding is important as it highlights the potential of Wegovy in helping individuals manage their relationship with food, which can be a crucial aspect of weight management and overall health.

Read full article

via Dow Jones - Health

Dow Jones - Health3 days ago

Novo Nordisk’s Diabetes Pill Gets EU Label Extension For Heart Benefits

PositiveHealth

Novo Nordisk's diabetes pill Rybelsus has received an EU label extension to officially include its heart benefits. This approval enhances its treatment profile for type 2 diabetes.

Editor’s Note: This matters because it not only expands the therapeutic options for patients with type 2 diabetes but also highlights the importance of cardiovascular health in diabetes management.

Read full article

via Dow Jones - Health

Latest from Health

The New York Times3 hours ago

Senator and Insurers Cast Doubt on U.S. Vaccine Panel as It Readies Review

NegativeHealth

Concerns are rising as a U.S. vaccine panel prepares for a critical review, with both senators and insurers expressing skepticism about its effectiveness and transparency. This scrutiny is significant because it could impact public trust in vaccination programs and influence future health policies, especially as the nation navigates ongoing health challenges.

Read full article

via The New York Times

NBC News4 hours ago

Former CDC official warns about changes to childhood vaccine schedule in hearing

NegativeHealth

A former CDC official raised concerns during a Senate health committee hearing about potential changes to the childhood vaccine schedule, particularly regarding the hepatitis B vaccine. This discussion is crucial as it could impact access to essential vaccinations for children, highlighting the ongoing debate over vaccine policies and public health.

Read full article

via NBC News

The New York Times4 hours ago

Susan Monarez, Fired C.D.C. Director, to Testify About Her Clash With Kennedy

NegativeHealth

Dr. Susan Monarez, the former director of the CDC, is set to testify at a Senate health committee hearing, where she will discuss her conflicts with Health Secretary Robert F. Kennedy Jr. Monarez's testimony highlights significant issues within the CDC, portraying Kennedy as ideologically driven and dismissive of scientific input. This clash is crucial as it raises concerns about the direction of public health policy and the role of scientific expertise in government decisions.

Read full article

via The New York Times

NBC News5 hours ago

Novo Nordisk aims for FDA approval of weight loss pill

PositiveHealth

Read full article

via NBC News

The New York Times5 hours ago

5 Takeaways From Ousted C.D.C. Director’s Hearing

NegativeHealth

In a recent Senate hearing, Susan Monarez, the newly appointed head of the CDC, expressed concerns about Health Secretary Robert F. Kennedy Jr.'s stance on vaccines, claiming he is disregarding scientific evidence. This matter is significant as it highlights the ongoing debate over vaccine efficacy and public health policy, especially in a time when trust in health authorities is crucial.

Read full article

via The New York Times

NBC News5 hours ago

Former CDC director says she was fired for refusing to rubber–stamp vaccine policies

NegativeHealth

Dr. Susan Monarez, the former director of the CDC, recently testified before Congress that she was dismissed by Robert F. Kennedy, Jr. for not endorsing vaccine policies without thorough scientific review. This revelation raises significant concerns about the integrity of public health decisions and the pressure on health officials to conform to political agendas, highlighting the ongoing debate over vaccine safety and efficacy.

Read full article

via NBC News